Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
3.
Clin Microbiol Infect ; 14(9): 879-82, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18844691

ABSTRACT

Five carbapenem-resistant Acinetobacter baumannii isolates, collected from the United Arab Emirates in 2006, were investigated to identify the mechanism(s) responsible for carbapenem resistance. Genotyping was performed by pulsed-field gel electrophoresis, and the location of the bla(OXA-23) gene was determined by using the endonuclease I CeuI technique and mating-out assays. The four isolates in which the bla(OXA-23) gene was located on the chromosome within a Tn2006 composite transposon were clonally related. The single non-clonally related isolate harboured the bla(OXA-23) gene on a 70-kb transferable plasmid. This study reports on the dissemination of OXA-23-producing A. baumannii isolates in the Middle East.


Subject(s)
Acinetobacter Infections/microbiology , Acinetobacter baumannii/drug effects , Acinetobacter baumannii/enzymology , Anti-Bacterial Agents/pharmacology , Carbapenems/pharmacology , beta-Lactam Resistance , beta-Lactamases/biosynthesis , Acinetobacter baumannii/isolation & purification , Adult , Chromosomes, Bacterial , Conjugation, Genetic , DNA Fingerprinting , DNA Transposable Elements , DNA, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Genotype , Humans , Middle Aged , Plasmids , United Arab Emirates
4.
J Virol ; 75(15): 7184-7, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11435599

ABSTRACT

Human foamy virus (HFV), a retrovirus of simian origin which occasionally infects humans, is the basis of retroviral vectors in development for gene therapy. Clinical considerations of how to treat patients developing an uncontrolled infection by either HFV or HFV-based vectors need to be raised. We determined the susceptibility of the HFV to dideoxynucleosides and found that only zidovudine was equally efficient against the replication of human immunodeficiency virus type 1 (HIV-1) and HFV. By contrast, zalcitabine (ddC), lamivudine (3TC), stavudine (d4T), and didanosine (ddI) were 3-, 3-, 30-, and 46-fold less efficient against HFV than against HIV-1, respectively. Some amino acid residues known to be involved in HIV-1 resistance to ddC, 3TC, d4T, and ddI were found at homologous positions of HFV reverse transcriptase (RT). These critical amino acids are located at the same positions in the three-dimensional structure of HIV-1 and HFV RT, suggesting that both enzymes share common patterns of inhibition.


Subject(s)
Antiviral Agents/pharmacology , Dideoxynucleosides/pharmacology , RNA-Directed DNA Polymerase/drug effects , Reverse Transcriptase Inhibitors/pharmacology , Spumavirus/drug effects , HIV Reverse Transcriptase/chemistry , Humans , Models, Molecular , Protein Structure, Secondary , RNA-Directed DNA Polymerase/chemistry , Sequence Analysis, Protein , Tumor Cells, Cultured
5.
Cell ; 100(3): 311-21, 2000 Feb 04.
Article in English | MEDLINE | ID: mdl-10676813

ABSTRACT

The release factor eRF1 terminates protein biosynthesis by recognizing stop codons at the A site of the ribosome and stimulating peptidyl-tRNA bond hydrolysis at the peptidyl transferase center. The crystal structure of human eRF1 to 2.8 A resolution, combined with mutagenesis analyses of the universal GGQ motif, reveals the molecular mechanism of release factor activity. The overall shape and dimensions of eRF1 resemble a tRNA molecule with domains 1, 2, and 3 of eRF1 corresponding to the anticodon loop, aminoacyl acceptor stem, and T stem of a tRNA molecule, respectively. The position of the essential GGQ motif at an exposed tip of domain 2 suggests that the Gln residue coordinates a water molecule to mediate the hydrolytic activity at the peptidyl transferase center. A conserved groove on domain 1, 80 A from the GGQ motif, is proposed to form the codon recognition site.


Subject(s)
Codon, Terminator , Peptide Chain Termination, Translational , Peptide Termination Factors/chemistry , RNA, Transfer, Amino Acyl/chemistry , RNA, Transfer/chemistry , Amino Acid Sequence , Crystallography , Humans , Hydrolysis , Models, Molecular , Molecular Mimicry , Molecular Sequence Data , Peptide Termination Factors/genetics , RNA, Transfer/metabolism , RNA, Transfer, Amino Acyl/metabolism , Recombinant Proteins/chemistry , Sequence Homology, Amino Acid
6.
Protein Eng ; 12(4): 313-8, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10325401

ABSTRACT

The class A beta-lactamase PER-1, which displays 26% identity with the TEM-type extended-spectrum beta-lactamases (ESBLs), is characterized by a substrate profile similar to that conferred by these latter enzymes. The role of residues Ala164, His170, Ala171, Asn179, Arg220, Thr237 and Lys242, found in PER-1, was assessed by site-directed mutagenesis. Replacement of Ala164 by Arg yielded an enzyme with no detectable beta-lactamase activity. Two other mutants, N179D and A164R+N179D, were also inactive. Conversely, a mutant with the A171E substitution displayed a substrate profile very similar to that of the wild-type enzyme. Moreover, the replacement of Ala171 by Glu in the A164R enzyme yielded a double mutant which was active, suggesting that Glu171 could compensate for the deleterious effect of Arg164 in the A164R+A171E enzyme. A specific increase in kcat for cefotaxime was observed with H170N, whereas R220L and T237A displayed a specific decrease in activity towards the same drug and a general increase in affinity towards cephalosporins. Finally, the K242E mutant displayed a kinetic behaviour very similar to that of PER-1. Based on three-dimensional models generated by homology modelling and molecular dynamics, these results suggest novel structure-activity relationships in PER-1, when compared with those previously described for the TEM-type ESBLs.


Subject(s)
Cephalosporins/metabolism , Mutagenesis, Site-Directed , beta-Lactamases/chemistry , Amino Acids/chemistry , DNA Primers , Escherichia coli/chemistry , Isoelectric Focusing , Kinetics , Models, Molecular , Protein Structure, Tertiary
7.
Biochemistry (Mosc) ; 64(12): 1360-6, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10648959

ABSTRACT

In protein synthesis, the arrival of one or other of the three stop codons in the ribosomal A-site triggers the binding of a release factor (RF) to the ribosome and subsequent polypeptide chain release. In eukaryotes, the RF is composed of two proteins, eRF1 and eRF3. eRF1 is responsible for the hydrolysis of the peptidyl-tRNA, while eRF3 provides a GTP-dependent function, although its precise role remains to be defined. Recent findings on translation termination and its regulation from studies in the yeast Saccharomyces cerevisiae are reviewed and the potential role of eRF3 is discussed.


Subject(s)
Peptide Chain Termination, Translational , Animals , Eukaryotic Cells , Humans , Peptide Termination Factors/metabolism , Prions/metabolism , Protein Structure, Tertiary , Saccharomyces cerevisiae/genetics , Saccharomyces cerevisiae/metabolism , Schizosaccharomyces/genetics , Schizosaccharomyces/metabolism
8.
Antimicrob Agents Chemother ; 42(12): 3113-6, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9835500

ABSTRACT

A clinical isolate of Pseudomonas aeruginosa, PAe191, was found to be highly resistant to all anti-Pseudomonas beta-lactam antibiotics (except imipenem) and resistant also to aminoglycosides. It produced a beta-lactamase (with an apparent pI of 7.6) which was not inhibited by clavulanic acid. Cloning and characterization of the beta-lactamase gene showed that it coded for a novel extended-spectrum OXA-10 variant, called OXA-19, which differed from OXA-10 by nine amino acids and from OXA-13 by two, i.e., Asn in position 73 (Asn73) instead of Ser and Asp157 instead of Gly. Asparagine in position 157 is implicated in resistance to ceftazidime, while the amino acid in position 73, in this variant, seems to condition the level of resistance to penicillins. The oxa19 gene was found to be inserted, in a typical integron structure, immediately downstream from an aac(6')-Ib gene coding for an aminoglycoside acetyltransferase variant, which was called AAC(6')-Ib9.


Subject(s)
Pseudomonas aeruginosa/enzymology , beta-Lactamases/metabolism , Amino Acid Sequence , Anti-Bacterial Agents/pharmacology , Cloning, Molecular , Drug Resistance, Microbial , Drug Resistance, Multiple , Escherichia coli/drug effects , Escherichia coli/enzymology , Isoelectric Focusing , Molecular Sequence Data , Plasmids , Pseudomonas aeruginosa/isolation & purification , beta-Lactamases/genetics , beta-Lactamases/isolation & purification , beta-Lactams
9.
Microbiology (Reading) ; 144 ( Pt 4): 1021-1031, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9579076

ABSTRACT

A clinical Pseudomonas aeruginosa strain, PAe391, was found to be resistant to a number of antibiotics including ticarcillin, piperacillin, cefsulodin and amikacin, and a disk diffusion assay showed evidence of pronounced synergy between imipenem and various beta-lactam antibiotics. Cloning and nucleotide sequence analysis revealed the dicistronic arrangement of an aac(6')-Ib variant and a novel blaOXA-type gene between the intI and qacE delta 1 genes typical of integrons, in PAe391, this integron was apparently chromosome-borne. The beta-lactamase, named OXA-13, displayed nine amino acid changes with respect to OXA-10:I in position 10 of OXA-10 to T (I10T), G20S, D55N, N73S, T107S, Y174F, E229G, S245N and E259A, OXA-13 (pIapp = 8.0) showed poor catalytic activity against penicillins as well as cephalosporins, but was efficient in hydrolysing some penicillinase-resistant beta-lactams, such as cefotaxime and aztreonam. It was efficiently inhibited by imipenem (KIapp = 11 nM), and formed a stable complex. While the KIapp value of meropenem was similar (16 nM), the corresponding complex was less stable.


Subject(s)
Anti-Bacterial Agents/pharmacology , Bacterial Outer Membrane Proteins/analysis , Carbapenems/pharmacology , Cephalosporinase/analysis , Genes, Bacterial/genetics , Pseudomonas aeruginosa/enzymology , beta-Lactamases/genetics , Bacterial Outer Membrane Proteins/genetics , Bacterial Outer Membrane Proteins/metabolism , Bacterial Outer Membrane Proteins/pharmacokinetics , Base Sequence , Cephalosporinase/genetics , Cephalosporinase/metabolism , Cephalosporinase/pharmacokinetics , Drug Resistance, Microbial/genetics , Humans , Immunoblotting , Molecular Sequence Data , Phenotype , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics , beta-Lactamase Inhibitors , beta-Lactamases/metabolism
10.
Antimicrob Agents Chemother ; 42(1): 108-13, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9449269

ABSTRACT

Klebsiella pneumoniae NEM865 was isolated from the culture of a stool sample from a patient previously treated with ceftazidime (CAZ). Analysis of this strain by the disk diffusion test revealed synergies between amoxicillin-clavulanate (AMX-CA) and CAZ, AMX-CA and cefotaxime (CTX), AMX-CA and aztreonam (ATM), and more surprisingly, AMX-CA and moxalactam (MOX). Clavulanic acid (CA) decreased the MICs of CAZ, CTX, and MOX, which suggested that NEM865 produced a novel extended-spectrum beta-lactamase. Genetic, restriction endonuclease, and Southern blot analyses revealed that the resistance phenotype was due to the presence in NEM865 of a 13.5-kb mobilizable plasmid, designated pNEC865, harboring a Tn3-like element. Sequence analysis revealed that the blaT gene of pNEC865 differed from blaTEM-1 by three mutations leading to the following amino acid substitutions: Glu104-->Lys, Met182-->Thr, and Gly238-->Ser (Ambler numbering). The association of these three mutations has thus far never been described, and the blaT gene carried by pNEC865 was therefore designated blaTEM-52. The enzymatic parameters of TEM-52 and TEM-3 were found to be very similar except for those for MOX, for which the affinity of TEM-52 (Ki, 0.16 microM) was 10-fold higher than that of TEM-3 (Ki, 1.9 microM). Allelic replacement analysis revealed that the combination of Lys104, Thr182, and Ser238 was responsible for the increase in the MICs of MOX for the TEM-52 producers.


Subject(s)
Anti-Bacterial Agents/pharmacology , Klebsiella pneumoniae/drug effects , Moxalactam/pharmacology , beta-Lactamases/genetics , Amino Acid Sequence , Anti-Bacterial Agents/metabolism , Cloning, Molecular , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Microbial Sensitivity Tests , Molecular Sequence Data , Moxalactam/metabolism , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid , beta-Lactam Resistance
11.
Antimicrob Agents Chemother ; 41(11): 2352-4, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9371332

ABSTRACT

Carbapenem resistance was studied in two sets of Citrobacter freundii strains: (i) strain CFr950, resistant to imipenem (MIC, 16 microg/ml) and isolated in vivo during imipenem therapy, and strain CFr950-Rev, the spontaneous, imipenem-susceptible revertant of CFr950 selected in vitro, and (ii) strains CFr801 and CFr802, two imipenem-resistant mutants selected in vitro from the susceptible clinical isolate CFr800. In all strains, whether they were imipenem-susceptible or -resistant strains, production of the cephalosporinase was derepressed and their Km values for cephaloridine were in the range of 128 to 199 microM. No carbapenemase activity was detected in vitro. The role of cephalosporinase overproduction in the resistance was demonstrated after introduction of the ampD gene which decreased the level of production of cephalosporinase at least 250-fold and resulted in an 8- to 64-fold decrease in the MICs of the carbapenems. The role of reduced permeability in the resistance was suggested by the absence, in CFr950 and CFr802, of two outer membrane proteins (the 42- and 40-kDa putative porins whose levels were considerably decreased in CFr801) and the reappearance of the 42-kDa protein in imipenem-susceptible strain CFr950-Rev. This role was confirmed after introduction of the ompF gene of Escherichia coli into the CFr strains, which resulted in 8- to 16-fold decreases in the MICs of carbapenems for CFr802 and CFr950. We infer from these results that the association of reduced, porin-mediated permeability with high-level cephalosporinase production, observed previously in other gram-negative bacteria, may also confer carbapenem resistance on C. freundii.


Subject(s)
Anti-Bacterial Agents/pharmacology , Citrobacter freundii/drug effects , Imipenem/pharmacology , Moxalactam/pharmacology , Thienamycins/pharmacology , Bacterial Outer Membrane Proteins/drug effects , Citrobacter freundii/enzymology , Citrobacter freundii/isolation & purification , Drug Resistance, Microbial , Meropenem , Microbial Sensitivity Tests , Plasmids/drug effects , beta-Lactamases/metabolism
12.
Antimicrob Agents Chemother ; 40(11): 2488-93, 1996 Nov.
Article in English | MEDLINE | ID: mdl-8913451

ABSTRACT

A clinical strain of Pseudomonas aeruginosa, PAe1100, was found to be resistant to all antipseudomonal beta-lactam antibiotics and to aminoglycosides, including gentamicin, amikacin, and isepamicin. PAe1100 produced two beta-lactamases, TEM-2 (pI 5.6) and a novel, TEM-derived extended-spectrum beta-lactamase called TEM-42 (pI 5.8), susceptible to inhibition by clavulanate, sulbactam, and tazobactam. Both enzymes, as well as the aminoglycoside resistance which resulted from AAC(3)-IIa and AAC(6')-I production, were encoded by an 18-kb nonconjugative plasmid, pLRM1, that could be transferred to Escherichia coli by transformation. The gene coding for TEM-42 had four mutations that led to as many amino acid substitutions with respect to TEM-2: Val for Ala at position 42 (Ala42), Ser for Gly238, Lys for Glu240, and Met for Thr265 (Ambler numbering). The double mutation Ser for Gly238 and Lys for Glu240, which has so far only been described in SHV-type but not TEM-type enzymes, conferred concomitant high-level resistance to cefotaxime and ceftazidime. The novel, TEM-derived extended-spectrum beta-lactamase appears to be the first of its class to be described in P. aeruginosa.


Subject(s)
Pseudomonas aeruginosa/enzymology , Amino Acids/analysis , Conjugation, Genetic , Isoelectric Focusing , Microbial Sensitivity Tests , Phenotype , Plasmids , Polymerase Chain Reaction , Polymorphism, Restriction Fragment Length , Pseudomonas aeruginosa/drug effects , Pseudomonas aeruginosa/genetics , Transformation, Bacterial
13.
Res Microbiol ; 146(9): 761-71, 1995.
Article in French | MEDLINE | ID: mdl-8584798

ABSTRACT

Of the 50 strains of beta-lactamase-producing Branhamella catarrhalis isolated at Saint Joseph's Hospital (Paris) that were studied, 94% produced BRO-1 type beta-lactamase and 6% produced the BRO-2 type. We examined the transfer of BRO-1 and BRO-2 genes and found that, among 7 donor strains producing BRO-1, all were able to transfer the gene for BRO-1 production by conjugation. Of the 4 donor strains producing BRO-2, 2 were able to transfer the gene for BRO-2 production by conjugation. Three BRO-1 beta-lactamase-producing transformants were obtained from total DNA extracted from 3 strains producing BRO-1. Plasmid bands were demonstrated in strains of B. catarrhalis, but no change in plasmid profiles was seen in beta-lactamase-positive recombinants, supporting previous studies that suggested the beta-lactamases are chromosomal. In vitro activity of oral beta-lactams was tested for 67 strains of B. catarrhalis (56 beta-lactamase-producing strains). Cefixime, cefpodoxime and the combination ampicillin-clavulanic acid were very active against the beta-lactamase-producing strains. BRO-1 beta-lactamase appears to affect the activity of cefaclor, cefuroxime and loracarbef. BRO-2 beta-lactamases have no effect on the activity of these cephalosporins. Cefixime and cefpodoxime seemed the least affected by beta-lactamase production.


Subject(s)
Anti-Bacterial Agents/pharmacology , DNA, Bacterial/chemistry , Moraxella catarrhalis/enzymology , Plasmids/genetics , beta-Lactamases/chemistry , Conjugation, Genetic , Drug Resistance, Microbial , Electrophoresis, Agar Gel , In Vitro Techniques , Isoelectric Focusing , Phenotype , Transformation, Genetic , beta-Lactamases/genetics , beta-Lactams
14.
Arch Fr Pediatr ; 50(6): 479-84, 1993.
Article in French | MEDLINE | ID: mdl-8135607

ABSTRACT

BACKGROUND: Obesity is a major Public Health problem in developed countries. It is frequently associated with psychological difficulties that may interfere with treatment. PATIENTS AND METHODS: 22 obese female adolescents, aged 13 to 19 years, and 24 age-matched female controls, were compared with regard to emotional pathology (anxiety, depression), eating behaviors, self-esteem, body image and parental history of depression. The evaluation was both categorical (DSM III-R criteria) and dimensional for depression and anxiety. It also included a self-esteem scale and questionnaires. RESULTS: The obese adolescents had more depressive symptoms, more prevalent anxiety disorders, more frequent histories of parental depression, eating behaviors characterized by over-eating and/or restricted intake, lower self-esteem and dissatisfaction with their body image, leading to avoidance behaviors in some of them. CONCLUSIONS: Psychological manifestations, although they are still insufficiently documented, especially in adolescents, may aggravate obesity and interfere with treatment.


Subject(s)
Adolescent Behavior , Feeding Behavior , Obesity/psychology , Adolescent , Anxiety Disorders/psychology , Body Image , Depressive Disorder/psychology , Female , Humans , Parent-Child Relations , Self Concept
15.
Pathol Biol (Paris) ; 36(3): 245-9, 1988 Mar.
Article in French | MEDLINE | ID: mdl-3283688

ABSTRACT

By studying the sensitivity to antibiotics of 74 Acinetobacter baumannii strains, four phenotype groups were distinguished. The resistance of one of them (11% of the strains) to imipenem, argues against the therapeutic attitudes that now prevail. From studies on the kinetics of bactericidal activity of antibiotics and there association we propose what should be done in the laboratory to provide help to the physician for the antibiotic choice.


Subject(s)
Acinetobacter/genetics , Acinetobacter/drug effects , Acinetobacter Infections/drug therapy , Amikacin/pharmacology , Anti-Bacterial Agents/pharmacology , Drug Resistance, Microbial/genetics , Gentamicins/pharmacology , Humans , Imipenem , Norfloxacin/analogs & derivatives , Norfloxacin/pharmacology , Pefloxacin , Phenotype , Thienamycins/pharmacology
16.
Br J Haematol ; 67(3): 285-91, 1987 Nov.
Article in English | MEDLINE | ID: mdl-3689694

ABSTRACT

Over 20 years, 58 cases of PV in young people (46 meeting the full PVSG criteria, 12 with elevated red cell volume and leucocytosis or thrombocytosis, without splenomegaly) were studied and have been followed for periods of 3-24 years. These cases represent approximately 5% of the cases of PV referred to the Department of Nuclear Medicine of St Louis Hospital during this period. They differ from older patients in the initial clinical severity, the short interval between the first symptoms and the diagnosis, frequent presentation with a life-threatening complication (two cases of hepatic vein thrombosis, six thrombotic or haemorrhagic events, six splenectomies, two abortions) and a very enlarged spleen in half the cases. However, after the initial complications, the overall survival is very long (exceeding 70%, even when including the initial complications, at 15 years). The vascular accidents occur exclusively in the phlebotomized patients, the main risk factor being the poor stability of the haematocrit. Only one acute leukaemia was observed among the 14 cases treated by radioactive phosphorus and/or alkylating chemotherapy. The most frequent late complication was evolution towards myelofibrosis. This spent phase seemed to occur earlier in patients treated by phlebotomy. On the basis of this data, we would advise the following therapeutic strategy: phlebotomies, as soon as the diagnosis is established, and a systematic long-term treatment by hydroxyurea with the hope of reducing the number of vascular complications and of delaying the evolution towards the spent phase and the myelofibrosis.


Subject(s)
Polycythemia Vera/diagnosis , Adult , Age Factors , Bloodletting , Female , Humans , Male , Polycythemia Vera/mortality , Polycythemia Vera/therapy , Postoperative Complications , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...